Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New results from the AEGEAN clinical trial offer good news to people with non-small cell lung cancer.
More than a third of people with predisposition genes for breast, ovarian or colon cancer would not have qualified for genetic screening.
Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets.
People treated with a durvalumab-based regimen before and after surgery had a 32% lower risk of disease recurrence or progression.
Genomic profiling showed patients with African ancestry had fewer actionable mutations and were less likely to qualify for immunotherapy.
Biliary tract cancers—rare malignancies arising in the gallbladder, bile ducts and related structures—are associated with poor outcomes.
Vaccines could potentially eliminate cervical, anal, oral and other cancers caused by human papillomavirus.
Model using artificial intelligence accurately predicted the risk of distant recurrence in people with endometrial cancer.
REGN5459 had decreased binding affinity to T cells, resulting in an encouraging side effect profile and efficacy.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
The multicancer early detection platform was developed based on methylation of cell-free DNA.
Desmoplastic melanoma, characterized by a high tumor mutation burden, may be uniquely sensitive to immune checkpoint inhibitors.
Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.